Doctors Note Logo

Published on: 8/18/2026

Understanding DMP1 and ENPP1 Gene Inheritance: How Recessive Variants Cause Phosphate Loss

DMP1 and ENPP1 variants cause autosomal recessive hypophosphatemic rickets (ARHR1 and ARHR2), meaning a child must inherit one altered copy from each parent, while carriers with a single variant typically show few or no symptoms. Both genes normally help regulate bone mineralization, and when they are disrupted, FGF23 levels rise and the kidneys leak phosphate into the urine, leading to low blood phosphate, soft bones, bowed legs, dental problems, and short stature. ENPP1 loss can also involve arterial calcification, so the inheritance pattern, timing of symptoms, and lab findings all matter when interpreting a diagnosis, and important details are explained below. Because phosphate wasting can also stem from X-linked, autosomal dominant, tumor-induced, or medication-related causes, sorting out your specific pattern of symptoms is the fastest route to the right testing. Take a free, instant, online symptom check to organize what you are experiencing and understand which next steps and specialists make sense for you.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Understanding DMP1 and ENPP1 Gene Inheritance: How Recessive Variants Cause Phosphate Loss

Autosomal recessive hypophosphatemic rickets (ARHR) is a rare bone disorder marked by low phosphate levels, weak bones and growth issues. Two key genes—DMP1 and ENPP1—play crucial roles in phosphate regulation. When both copies of either gene carry damaging (recessive) variants, phosphate balance is disrupted, leading to ARHR. This article explains how DMP1 and ENPP1 function, how their recessive variants cause phosphate loss, and what this means for affected individuals and families.

Normal Role of DMP1 and ENPP1

Phosphate is vital for strong bones, muscle function and energy production. The body tightly controls phosphate through:

  • Intestine: absorption of dietary phosphate
  • Kidney: reabsorption or excretion of phosphate
  • Bone: storage and release of phosphate

DMP1 (Dentin Matrix Protein 1) and ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) help regulate these processes, mainly by influencing FGF23, a hormone that tells kidneys to excrete phosphate.

DMP1

  • Produced by bone-forming cells (osteocytes).
  • Keeps FGF23 levels in check.
  • Supports mineralization of bone matrix.

ENPP1

  • Generates pyrophosphate, which prevents unwanted mineral deposits in soft tissues.
  • Influences the balance between pyrophosphate (PPi) and phosphate (Pi).
  • Helps regulate FGF23 production indirectly.

Autosomal Recessive Inheritance

“Autosomal recessive” means a person must inherit two non-working (pathogenic) copies of a gene—one from each parent—to develop ARHR. Parents carrying one altered DMP1 or ENPP1 have a 50% chance of passing that variant to each child but typically don’t show symptoms.

Inheritance pattern:

  • Both parents are carriers (each has one normal and one altered copy).
  • For each pregnancy:
    • 25% chance the child inherits both altered copies (affected).
    • 50% chance the child inherits one altered copy (carrier, unaffected).
    • 25% chance the child inherits both normal copies (unaffected, not a carrier).

How Recessive Variants Lead to Phosphate Loss

When both copies of DMP1 or ENPP1 carry damaging changes, the normal checks on FGF23 and mineral balance fail.

DMP1-Related ARHR (ARHR1)

  1. Loss of DMP1 function in bone cells.
  2. Uncontrolled rise in FGF23 production.
  3. Kidneys excrete too much phosphate.
  4. Low blood phosphate (hypophosphatemia) leads to soft bones and rickets.

ENPP1-Related ARHR (ARHR2)

  1. Reduced pyrophosphate production allows overactive mineralization signals.
  2. Dysregulated FGF23 levels (often elevated).
  3. Accelerated phosphate loss via kidneys.
  4. Similar bone symptoms to ARHR1, though some patients may also have calcification in blood vessels (due to PPi deficiency).

Clinical Features of ARHR

Symptoms usually begin in infancy or early childhood. Key signs include:

  • Bone pain and tenderness
  • Delayed growth and short stature
  • Bowing of legs (genu varum)
  • Dental abnormalities (weak enamel, abscesses)
  • Muscle weakness or fatigue
  • Frequent fractures

ARHR2 (ENPP1) may also present with:

  • Soft tissue or vascular calcifications
  • Hearing loss (in rare cases)

Diagnosis

A thorough evaluation involves:

  1. Medical history and physical exam

    • Family history of rickets or bone disease
    • Growth measurements, bone deformity assessment
  2. Blood tests

    • Low phosphate (hypophosphatemia)
    • Normal or low vitamin D levels
    • Elevated FGF23 (if available)
    • Normal calcium and parathyroid hormone
  3. Urine tests

    • High phosphate excretion
  4. Imaging

    • X-rays show rickets signs (widened growth plates, bowing)
  5. Genetic testing

    • Confirms recessive variants in DMP1 or ENPP1
    • Guides family planning and carrier screening

Treatment and Management

While there’s no cure, early and consistent treatment can improve outcomes:

• Phosphate supplements
– Taken multiple times daily to raise blood phosphate
• Active vitamin D analogs (e.g., calcitriol)
– Enhances intestinal phosphate absorption
• Regular monitoring
– Blood levels (phosphate, calcium)
– Growth and bone health
• Physical therapy
– Supports mobility and muscle strength
• Orthopedic interventions
– Bracing or surgery for severe bone deformities

Emerging therapies targeting FGF23 (like burosumab) have shown promise in related conditions but are under investigation for ARHR.

Genetic Counseling and Family Planning

Families with ARHR benefit from genetic counseling to understand:

  • Carrier risk for siblings and future children
  • Options for prenatal or preimplantation genetic testing
  • Implications for extended family members

Counselors can explain how autosomal recessive inheritance works and support informed decisions.

When to Seek Medical Attention

If you or your child have symptoms such as bone pain, delayed growth or unusual fractures, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. Early evaluation by a healthcare provider can help confirm a diagnosis and start treatment sooner.

Always speak to a doctor about any serious symptoms or life-threatening concerns. Timely medical advice is essential for managing ARHR and preventing complications.

Living with ARHR

With proper care, many people with ARHR lead active lives. Key strategies include:

  • Sticking to medication schedules
  • Regular follow-up with an endocrinologist or metabolic bone specialist
  • Adapting physical activities to minimize fracture risk
  • Joining support groups for shared experiences and resources

Summary

Autosomal recessive hypophosphatemic rickets (ARHR) arises when both copies of DMP1 or ENPP1 carry recessive variants. These genes normally keep phosphate levels balanced by regulating FGF23 and mineralization. Pathogenic variants lead to unchecked phosphate loss, causing weak bones, growth delays and rickets. Diagnosis relies on lab tests, imaging and genetic confirmation. Treatment focuses on phosphate and active vitamin D supplementation, plus supportive therapies. Genetic counseling helps families understand risks and options.

Early recognition and consistent care are vital. If you notice symptoms suggestive of hypophosphatemic rickets, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And always consult a healthcare professional if you have questions or serious health concerns—especially anything that could be life threatening.

(References)

  • * Christov M, Jüppner H. Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):685-706. doi: 10.1016/j.beem.2018.06.004. Epub 2018 Jun 18. PMID: 30449549.

  • * Baroncelli GI, Toschi B, Bertelloni S. Hypophosphatemic rickets. Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):460-7. doi: 10.1097/MED.0b013e328358be97. PMID: 23108197.

  • * Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.

  • * Wagner SA, Panzer M, Pertler E, Redl S, Saretto M, Schaefer B, Pammer LM, Obholzer L, Troppmair MR, Hess MW, Salvenmoser W, Degenhart G, Grossgut M, Talasz H, Faserl K, Sarg B, Haubner R, Hartmann MA, Blouin S, Petzer V, Gronich-Wondrak P, Kronbichler A, Manzl C, Glodny B, Tilg H, Franke A, Wolf M, Hadjihannas MV, Zoller H. Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia. Blood. 2026 Jul 2;148(1):15-30. doi: 10.1182/blood.2025031806. PMID: 41849242; PMCID: PMC13389865.

  • * Bacchetta J, Amouroux C. ENPP1 deficiency: almost ready for prime time! Arch Pediatr. 2024 Sep;31(4S1):4S1-4S2. doi: 10.1016/S0929-693X(24)00150-7. PMID: 39343467.

  • * Courbon G, Kentrup D, Thomas JJ, Wang X, Tsai HH, Spindler J, Von Drasek J, Ndjonko LM, Martinez-Calle M, Lynch S, Hivert L, Wang X, Chang W, Feng JQ, David V, Martin A. FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice. JCI Insight. 2023 Dec 22;8(24). doi: 10.1172/jci.insight.156850. Epub 2023 Dec 22. PMID: 37943605; PMCID: PMC10807721.

  • * Baujat G, Besançon A. Generalized Arterial Calcification of Infancy (GACI). Arch Pediatr. 2024 Sep;31(4S1):4S21-4S26. doi: 10.1016/S0929-693X(24)00153-2. PMID: 39343469.

  • * Toyosawa S, Oya K, Sato S, Ishida K. [Osteocyte and DMP1]. Clin Calcium. 2012 May;22(5):713-20. PMID: 22549196.

  • * Rowe PS, McCarthy EM, Yu AL, Stubbs JR. Correction of Vascular Calcification and Hyperphosphatemia in CKD Rats Treated with ASARM Peptide. Kidney360. 2022 Oct 27;3(10):1683-1698. doi: 10.34067/KID.0002782022. Epub 2022 Aug 30. PMID: 36514737; PMCID: PMC9717652.

  • * Ferreira CR, Carpenter TO, Braddock DT. ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency. Annu Rev Pathol. 2024 Jan 24;19:507-540. doi: 10.1146/annurev-pathmechdis-051222-121126. Epub 2023 Oct 23. PMID: 37871131; PMCID: PMC11062289.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.